CytomX Therapeutics (6C1) Stock Forecast & Price Target
6C1 Analyst Ratings
6C1 Stock 12 Month Forecast
Average Price Target
EUR 11.61▲(479.77% Upside)Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | EUR 14.29 | buy | 613.57%Upside | Reiterated | 10/27/26 | ||
| Olivia Brayer | Cantor Fitzgerald | EUR 10.71 | buy | 435.17%Upside | Reiterated | 10/13/26 | ||
| Edward Tenthoff | Piper Sandler | EUR 10.71 | buy | 435.17%Upside | Reiterated | 09/23/26 | ||
| Anupam Rama | J.P. Morgan | EUR 9.82 | buy | 390.58%Upside | Reiterated | 08/17/26 | ||
| Michael Schmidt | Guggenheim | EUR 13.39→EUR 12.50 | buy | 524.37%Upside | Reiterated | 08/07/26 | ||
| Robert Driscoll | Wedbush | EUR 9.82 | buy | 390.58%Upside | Reiterated | 06/04/26 | ||
| Kalpit Patel | Wolfe Research | EUR 5.36 | buy | 167.59%Upside | Initiated | 05/19/26 | ||
| Mitchell Kapoor | H.C. Wainwright | EUR 15.18→EUR 9.82 | buy | 390.58%Upside | Reiterated | 05/11/26 | ||
| Roger Song | Jefferies | EUR 7.14→EUR 14.29 | buy | 613.57%Upside | Reiterated | 03/18/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | 10/27/26 | EUR 14.29 | buy | 613.57%Upside | Reiterated | Barclays | ||
| Olivia Brayer | 10/13/26 | EUR 10.71 | buy | 435.17%Upside | Reiterated | Cantor Fitzgerald | ||
| Edward Tenthoff | 09/23/26 | EUR 10.71 | buy | 435.17%Upside | Reiterated | Piper Sandler | ||
| Anupam Rama | 08/17/26 | EUR 9.82 | buy | 390.58%Upside | Reiterated | J.P. Morgan | ||
| Michael Schmidt | 08/07/26 | EUR 13.39→EUR 12.50 | buy | 524.37%Upside | Reiterated | Guggenheim | ||
| Robert Driscoll | 06/04/26 | EUR 9.82 | buy | 390.58%Upside | Reiterated | Wedbush | ||
| Kalpit Patel | 05/19/26 | EUR 5.36 | buy | 167.59%Upside | Initiated | Wolfe Research | ||
| Mitchell Kapoor | 05/11/26 | EUR 15.18→EUR 9.82 | buy | 390.58%Upside | Reiterated | H.C. Wainwright | ||
| Roger Song | 03/18/26 | EUR 7.14→EUR 14.29 | buy | 613.57%Upside | Reiterated | Jefferies |
Best Analysts Covering CytomX Therapeutics
Copying Etzer Darout's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +7.61% per trade.
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +14.09% per trade.
Copying Robert Driscoll's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -6.85% per trade.
6C1 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 6 | 6 | 8 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 10 | 7 | 6 | 8 |
In the current month, 6C1 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6C1 average Analyst price target in the past 3 months is 11.61.
6C1 Financial Forecast
6C1 Earnings Forecast
Next quarter’s earnings estimate for 6C1 is -EUR 0.06 with a range of -EUR 0.10 to EUR 0.03. The previous quarter’s EPS was -EUR 0.08. 6C1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.
6C1 Sales Forecast
Next quarter’s sales forecast for 6C1 is EUR 9.26M with a range of EUR 1.39M to EUR 33.02M. The previous quarter’s sales results were EUR 1.27M. 6C1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.